Metastatic Brain Tumors

Metastatic brain tumors, or brain metastases, are secondary tumors that spread to the brain from a cancer elsewhere in the body. They are collectively the most common intracranial tumors in adults and typically present as one or several enhancing masses, most often originating from lung, breast, melanoma, kidney, and colorectal primaries.

Definition

A metastatic brain tumor is a secondary intracranial neoplasm formed by cancer cells that have spread to the brain from a primary tumor elsewhere in the body, in contrast to a primary brain tumor that originates within the central nervous system.

Scope

The entry covers brain metastases as a category distinct from primary brain tumors: their hematogenous spread and predilection for the gray-white junction, the difference between single and multiple lesions, the prognostic tools used to stratify patients, and the roles of surgery, radiosurgery, and whole-brain radiotherapy. It is a reference description, not clinical guidance.

Core questions

• How do brain metastases differ from primary brain tumors in origin and behavior?
• Why do metastases favor the junction between gray and white matter?
• How does the number of lesions influence the choice among surgery, radiosurgery, and whole-brain radiotherapy?
• What prognostic tools stratify expected survival across primary cancer types?

Key concepts

• Hematogenous spread to the brain
• Gray-white matter junction predilection
• Single versus multiple metastases
• Surgical resection of accessible lesions
• Stereotactic radiosurgery
• Whole-brain radiotherapy
• Graded Prognostic Assessment

Mechanisms

Cancer cells reach the brain chiefly through the bloodstream and tend to lodge at the junction between gray and white matter, where the caliber of blood vessels narrows, producing well-circumscribed enhancing masses often surrounded by edema. The clinical picture depends on the number, size, and location of lesions and on mass effect. Management is shaped by whether disease is single or multiple, by the status of the systemic cancer, and by performance status; landmark randomized trials established that resecting a single accessible metastasis improves outcomes and that radiotherapy after resection reduces local recurrence. Prognosis varies markedly by primary tumor type and is summarized by diagnosis-specific tools such as the Graded Prognostic Assessment.

Clinical relevance

Brain metastases illustrate how secondary intracranial disease is conceptualized separately from primary tumors and how prognosis and management depend on the underlying cancer, lesion burden, and systemic status. This entry describes the category and its evidence base for educational orientation and is not a basis for individual diagnostic or treatment decisions.

Epidemiology

Brain metastases are the most common intracranial tumors in adults, collectively exceeding primary brain tumors in incidence; the most frequent sources are lung and breast cancers and melanoma, and their detection has risen with improved imaging and longer survival from systemic cancer therapies.

Evidence & guidelines

Randomized trials by Patchell and colleagues established the value of resecting single metastases and of postoperative radiotherapy, and the trial by Mahajan and colleagues supported postoperative stereotactic radiosurgery to the resection cavity. The Graded Prognostic Assessment provides diagnosis-specific survival estimates, and the Society for Neuro-Oncology consensus review synthesizes current management.

History

Management of brain metastases shifted from whole-brain radiotherapy alone toward targeted local strategies after Patchell's 1990 trial showed a benefit from resecting single metastases and his 1998 trial showed that postoperative radiotherapy reduced recurrence. The subsequent development of stereotactic radiosurgery and diagnosis-specific prognostic tools, together with advances in systemic therapy, reshaped the field toward individualized, lesion-directed care.

Debates

When should whole-brain radiotherapy be used versus focal radiosurgery?

Whole-brain radiotherapy treats microscopic disease but carries cognitive cost, while stereotactic radiosurgery spares uninvolved brain; the balance between them, especially with multiple lesions, remains an evolving area of evidence.

How should prognosis guide intensity of local treatment?

Because survival varies widely by primary cancer and patient factors, prognostic tools such as the Graded Prognostic Assessment are used to match the intensity of local therapy to expected benefit, a judgement that continues to be refined.

Key figures

• Roy A. Patchell
• Paul W. Sperduto
• Ayal A. Aizer

Seminal works

• patchell-1990
• patchell-1998
• sperduto-2012

Frequently asked questions

How are metastatic brain tumors different from primary brain tumors?

Metastatic brain tumors spread to the brain from a cancer that began elsewhere in the body, whereas primary brain tumors originate within the central nervous system itself; this difference shapes their behavior, prognosis, and management.

Which cancers most often spread to the brain?

Lung and breast cancers and melanoma are among the most frequent sources of brain metastases, followed by kidney and colorectal cancers, though many cancer types can spread to the brain.